Every 424B that Intelligent Bio Solutions Inc. (INBS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow INBS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INBS filings page.
Intelligent Bio Solutions Inc. (INBS) registered 6,211,809 common shares for resale by selling stockholders, all issuable upon exercise of warrants from its September 2026 private placement. The shares comprise 2,036,659 under each of the Series M Pre-Funded, Series N-1 and Series N-2 Warrants, plus 101,832 under Placement Agent Warrants. The Series M, Series N-1 and Placement Agent Warrants are immediately exercisable; Series N-2 Warrants are exercisable after stockholder approval, which INBS agreed to seek at a meeting on or before December 31, 2026.
INBS receives no proceeds from resales, but may receive proceeds from cash warrant exercises and intends to use them for working capital and general corporate purposes. If all specified warrants are exercised for cash, the company estimates gross proceeds of approximately $9.82 million. INBS reported approximately $5.0 million in gross proceeds from the private placement, before fees and expenses and excluding warrant-exercise proceeds. The auditor's report on the incorporated financial statements includes an explanatory paragraph regarding the company's ability to continue as a going concern.
Intelligent Bio Solutions, Inc. is offering up to $3,966,316 of common stock through an at-the-market program with Ladenburg Thalmann & Co. Inc., allowing sales from time to time on Nasdaq or other U.S. trading markets. The supplement states $3,966,316 remains available under the ATM Agreement.
The supplement reports a public float of $18,572,023 based on March 23, 2026 data and 1,910,702 shares held by non-affiliates, and a last sale price of $3.43 per share on March 20, 2026. Proceeds are intended for working capital and general corporate purposes. The filing discloses substantial doubt about the company’s ability to continue as a going concern, citing cash and receivable balances and the need for additional financing.
Intelligent Bio Solutions Inc. is registering 6,896,550 shares of common stock for resale by existing investors. These shares consist of 105,000 shares already outstanding and 6,791,550 shares issuable upon exercise of Series L Pre-Funded Warrants and Series K‑1 and K‑2 common stock purchase warrants that were issued in a December 31, 2025 private placement. The company will not receive any proceeds from the resale of these shares, but could receive up to approximately $18.87 million if all 6,791,550 warrant shares are exercised for cash.
The private placement raised about $10.0 million in gross proceeds for working capital and general corporate purposes. As of January 2, 2026, 1,216,142 shares of common stock were outstanding. The filing notes that the resale represents a large block relative to current outstanding shares and could pressure the stock price if sold quickly. The company recently completed a 1‑for‑10 reverse stock split and has regained compliance with Nasdaq’s $1.00 minimum bid price requirement.